Terms: = Ovarian cancer AND FAT1, CDHF7, 2195, ME5, hFat1, CDHR8
5 results:
1. Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human cancer Reference panel identifies a malignant signature.
Mhawech-Fauceglia P; Izevbaye I; Spindler T; Wang G; Hwang H; Samrao D; Elishaev E; Maxwell GL; Lawrenson K; Darcy KM
Gynecol Oncol; 2020 Jan; 156(1):6-12. PubMed ID: 31711656
[TBL] [Abstract] [Full Text] [Related]
2. Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer.
Harding BN; Delaney JA; Urban RR; Weiss NS
Gynecol Oncol; 2019 Aug; 154(2):426-431. PubMed ID: 31178150
[TBL] [Abstract] [Full Text] [Related]
3. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Hodgson DR; Dougherty BA; Lai Z; Fielding A; Grinsted L; Spencer S; O'Connor MJ; Ho TW; Robertson JD; Lanchbury JS; Timms KM; Gutin A; Orr M; Jones H; Gilks B; Womack C; Gourley C; Ledermann J; Barrett JC
Br J Cancer; 2018 Nov; 119(11):1401-1409. PubMed ID: 30353044
[TBL] [Abstract] [Full Text] [Related]
4. Tibolone and risk of gynecological hormone sensitive cancer.
Løkkegaard ECL; Mørch LS
Int J Cancer; 2018 Jun; 142(12):2435-2440. PubMed ID: 29349823
[TBL] [Abstract] [Full Text] [Related]
5. Comparative integromics on fat1, FAT2, FAT3 and FAT4.
Katoh Y; Katoh M
Int J Mol Med; 2006 Sep; 18(3):523-8. PubMed ID: 16865240
[TBL] [Abstract] [Full Text] [Related]
